Innovation Drives European Transcatheter Embolization and Occlusion Market Growth
According to a report published by Millennium Research Group (MRG), the European market for transcatheter embolization and occlusion (TEO) devices, including embolization coils and particles, liquid embolics, coiling-assist devices, guidewires and catheters, and heart defect closure devices, generated over $125 million in 2004.
June 30, 2005—Europe’s aging population is increasingly susceptible to cancer
and cardiovascular disease, generating a growing demand for effective medical
treatments. Medical manufacturers have responded with the development of a range
of new embolization and occlusion technologies to treat aneurysms, uterine
fibroids, tumors, and a host of other conditions.
According to a report
published by Millennium Research Group (MRG), the European market for
transcatheter embolization and occlusion (TEO) devices, including embolization
coils and particles, liquid embolics, coiling-assist devices, guidewires and
catheters, and heart defect closure devices, generated over $125 million in
2004.
Despite the limitations imposed by physician referral patterns,
minimal reimbursement, and the absence of long-term clinical data, the
continuing adoption of innovative, premium-priced devices, such as endovascular
cerebral aneurysm coils, microspheres, and heart defect closure devices, will
support 10% annual TEO market growth through 2009.
MRG’s European Markets
for Transcatheter Embolization and Occlusion Devices 2005 examines the
innovations transforming interventional neuroradiology (INR), peripheral
vascular (PV), and interventional cardiology (IC) procedures across Europe. The
report identifies the technologies that will drive revenue growth over the next
five years and the competitors poised to capitalize on these
opportunities.
As the leader in multiple segments of the TEO market,
Boston Scientific currently holds—and should maintain—a distinct competitive
advantage in Europe. Thanks to the strong performance of its Amplatzer heart
defect closure devices, AGA Medical trailed only Boston Scientific in total
European TEO revenues in 2004. MRG’s new report also examines other key
competitors in the TEO market, including Cordis, Micro Therapeutics, Inc.,
Terumo, Micrus Corporation, Cook, Microvention, Inc., Cardia, Inc., BioSphere
Medical, NMT Medical, Balt, W.L. Gore, and ev3.
A leading source of
competitive intelligence, MRG is now the largest provider of medical device
market research in the world. Located in Toronto, Canada, MRG covers global
markets and has pioneered reporting of numerous emerging
products.
Contact Information:
Derrick Navarro
Millennium Research
Group Inc.
(416) 364-7776 ext. 133
e-mail protected from spam bots
www.mrg.net
# # #
Source : http://www.prweb.com/releases/2005/6/prweb256333.htm